MX2023004940A - Proceso para preparar compuestos de metanona heterocíclicos e intermediarios aza-biciclo de los mismos. - Google Patents

Proceso para preparar compuestos de metanona heterocíclicos e intermediarios aza-biciclo de los mismos.

Info

Publication number
MX2023004940A
MX2023004940A MX2023004940A MX2023004940A MX2023004940A MX 2023004940 A MX2023004940 A MX 2023004940A MX 2023004940 A MX2023004940 A MX 2023004940A MX 2023004940 A MX2023004940 A MX 2023004940A MX 2023004940 A MX2023004940 A MX 2023004940A
Authority
MX
Mexico
Prior art keywords
aza
bicyclo
intermediates
compounds
methanone compounds
Prior art date
Application number
MX2023004940A
Other languages
English (en)
Spanish (es)
Inventor
Christian Grugel
Original Assignee
Actinogen Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020904060A external-priority patent/AU2020904060A0/en
Application filed by Actinogen Medical Ltd filed Critical Actinogen Medical Ltd
Publication of MX2023004940A publication Critical patent/MX2023004940A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B49/00—Grignard reactions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023004940A 2020-11-06 2021-11-05 Proceso para preparar compuestos de metanona heterocíclicos e intermediarios aza-biciclo de los mismos. MX2023004940A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020904060A AU2020904060A0 (en) 2020-11-06 Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof
PCT/AU2021/051310 WO2022094668A1 (en) 2020-11-06 2021-11-05 Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof

Publications (1)

Publication Number Publication Date
MX2023004940A true MX2023004940A (es) 2023-09-12

Family

ID=81458249

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004940A MX2023004940A (es) 2020-11-06 2021-11-05 Proceso para preparar compuestos de metanona heterocíclicos e intermediarios aza-biciclo de los mismos.

Country Status (11)

Country Link
US (1) US20230416243A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240740A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023548368A (cg-RX-API-DMAC7.html)
KR (1) KR20230154789A (cg-RX-API-DMAC7.html)
CN (1) CN116981461A (cg-RX-API-DMAC7.html)
AU (1) AU2021374232A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196642A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001300A1 (cg-RX-API-DMAC7.html)
IL (1) IL302671A (cg-RX-API-DMAC7.html)
MX (1) MX2023004940A (cg-RX-API-DMAC7.html)
WO (1) WO2022094668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026509196A (ja) * 2023-03-02 2026-03-17 アクチノゲン メディカル リミテッド アザ二環式ヘテロアリール化合物を調製するための流動化学プロセス
CN121969372A (zh) * 2023-10-03 2026-05-01 射线质医疗有限公司 片剂制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1732552A4 (en) * 2004-01-20 2007-12-19 Merck & Co Inc 2,6-DISUBSTITUTED PIPERIDINES AS MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
ES2366058T3 (es) * 2006-03-01 2011-10-14 Theravance, Inc. Compuestos de 8-azabiciclo[3.2.1]octano como antagonistas de los receptores opioides mu.
CA2738453C (en) * 2008-10-23 2017-07-04 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
DK2477983T3 (en) * 2009-09-16 2015-06-29 Univ Edinburgh (4-phenyl-piperidin-1-yl) - [5-1H-pyrazol-4-yl) -thiophene-3-yl] -METHANONFORBINDELSER AND THEIR USE
AU2010331927B2 (en) * 2009-12-17 2013-10-10 Merck Canada Inc. Aminopyrimidines as Syk inhibitors
WO2011090935A1 (en) * 2010-01-19 2011-07-28 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
BR112012027640B1 (pt) * 2010-04-29 2021-08-03 The University Of Edinburgh Composto, composição farmacêutica, e, métodos de preparar uma composição farmacêutica, de inibir a função da 11beta-hidroxiesteroide desidrogenase do tipo 1

Also Published As

Publication number Publication date
EP4240740A4 (en) 2024-12-11
US20230416243A1 (en) 2023-12-28
CN116981461A (zh) 2023-10-31
EP4240740A1 (en) 2023-09-13
IL302671A (en) 2023-07-01
AU2021374232A9 (en) 2024-09-26
CA3196642A1 (en) 2022-05-12
WO2022094668A1 (en) 2022-05-12
CL2023001300A1 (es) 2024-01-05
JP2023548368A (ja) 2023-11-16
KR20230154789A (ko) 2023-11-09
AU2021374232A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
US5034398A (en) 1H-indazole-3-carboxamide-N-2-azabicyclo[2.2.2]octanes useful for treating anxiety, psychosis, neuralgia, migraine and cluster headaches
AU745964B2 (en) 8-Azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ACh receptors
US5686463A (en) Oxadiazoles useful in the treatment of senile dementia
US4798829A (en) 1-Azabicyclo[3,2,2]nonane derivatives having 5-HT receptor antagonist activity
US4808588A (en) Heterocyclic ureas and carbonates useful as pharmaceuticals
US5541194A (en) Certain 1-azabicyclo[2.2.1]heptanes and 1-azabicyclo[2.2.2]octanes
US4822795A (en) Pharmaceutically useful esters and amides
AU617785B2 (en) Spirocyclic compounds incorporating five-membered rings with two heteroatoms
HU193725B (en) Process for producing benzoic acid and indocarboxylic acid derivatives and pharmaceutical compositions containing them
US7538132B2 (en) Isoxazolo derivatives
JP2007269811A (ja) 化学的シナプス伝達の制御に有用なフロピリジン、チエノピリジン、ピロロピリジンおよび関連するピリミジン、ピリダジンおよびトリアジン化合物
AU2004249441B2 (en) Novel 8-aza-bicyclo(3.2.1)octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CL2023001300A1 (es) Proceso para preparar compuestos de metanona heterocíclicos e intermediarios aza-bicyclo de los mismos
EP1638939A2 (en) Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US5324724A (en) Compounds for the treatment of senile dementia
MX2025009864A (es) Proceso de quimica de flujo para preparar compuestos de heteroarilo aza-biciclico
US5200413A (en) Indolyl carboxamides useful treating migraine, cluster headache, trigeminal neuralgia or emesis
US5470859A (en) Azabicyclic compounds with muscarinic activity useful for treating dementia
AU2004212166B2 (en) 8-aza-bicyclo (3.2.1) octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2627546A1 (en) 3 -monosubstituted tropane derivatives as nociceptin receptor ligands
Zhai et al. Construction of protected hydroxylated pyrrolidines using nitrogen-centered radical cyclizations
IE84087B1 (en) Novel compounds